SIH Partners’s Royalty Pharma RPRX Stock Holding History

SIH Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-26,881	Closed	-$837K	–	281
2025 Q1	$837K	Buy	+26,881	New	+$852K	0.03%	133

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

SIH Partners's RPRX Position: Q2 2025 in Review

SIH Partners sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 26,881 shares — an estimated $837K sold.

SIH Partners first reported a position in RPRX in Q1 2025 and held it in 1 quarter. The position peaked at $837K in Q1 2025. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

SIH Partners reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 26,881 Royalty Pharma shares in Q2 2025, an estimated $837K.
SIH Partners first reported a position in Royalty Pharma in Q1 2025 and held it in 1 quarter.
SIH Partners's Royalty Pharma position peaked at $837K in Q1 2025.
455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.